Normal view MARC view ISBD view

Immunomodulators for Non-Melanoma Skin Cancers: Updated Perspectives. [Review]

MedStar author(s):

Citation: Clinical, Cosmetic and Investigational Dermatology CCID. 16:1025-1045, 2023.PMID: 37095898Department: Dermatology | MedStar Outpatient CareForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: Year: 2023 ISSN:

1178-7015

Name of journal: Clinical, cosmetic and investigational dermatologyAbstract: Non-melanoma skin cancers (NMSCs) are the most common cancers worldwide and may be associated with significant morbidity and mortality, especially in immunosuppressed populations. Successful management of NMSC must take primary, secondary and tertiary prevention strategies into consideration. In response to an improved understanding of the pathophysiology of NMSC and associated risk factors, multiple systemic and topical immunomodulatory drugs have been developed and integrated into clinical practice. Many of these drugs are efficacious in the prevention and treatment of precursor lesions (actinic keratoses; AKs), low-risk NMSC, and advanced disease. The identification of patients at high risk for the development of NMSC is critical in reducing disease morbidity. Understanding the various treatment options available and their comparative effectiveness is paramount for developing a personalized treatment regimen for such patients. This review article provides an updated overview of the various topical and systemic immunomodulatory drugs available for the prevention and treatment of NMSC, and the published data supporting their use in clinical practice. Copyright Â© 2023 Russomanno et al.All authors: Russomanno K, Abdel Azim S, Patel VAFiscal year: FY2023 Digital Object Identifier:

https://dx.doi.org/10.2147/CCID.S362171

ORCID:

https://orcid.org/0000-0003-1257-6405

Date added to catalog: 2023-06-26

Holdings ( 1 )
Title notes ( 2 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	37095898	Available		37095898

Non-melanoma skin cancers (NMSCs) are the most common cancers worldwide and may be associated with significant morbidity and mortality, especially in immunosuppressed populations. Successful management of NMSC must take primary, secondary and tertiary prevention strategies into consideration. In response to an improved understanding of the pathophysiology of NMSC and associated risk factors, multiple systemic and topical immunomodulatory drugs have been developed and integrated into clinical practice. Many of these drugs are efficacious in the prevention and treatment of precursor lesions (actinic keratoses; AKs), low-risk NMSC, and advanced disease. The identification of patients at high risk for the development of NMSC is critical in reducing disease morbidity. Understanding the various treatment options available and their comparative effectiveness is paramount for developing a personalized treatment regimen for such patients. This review article provides an updated overview of the various topical and systemic immunomodulatory drugs available for the prevention and treatment of NMSC, and the published data supporting their use in clinical practice. Copyright Â© 2023 Russomanno et al.

English